NCT00746746 2011-01-13A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced MelanomaOchsner Health SystemPhase 2 Unknown30 enrolled